Drawing First Blood

We invite two experts to debate controversial topics in hematology and health care.

  • To Test or Not to Test: Is Pharmacogenomic Testing for Warfarin Valuable? Tuesday, November 22nd, 2016 | December 2016, Volume 2, Issue 12 | Larisa H. Cavallari, PharmD

    Warfarin has been standard anticoagulation for more than 60 years, but the significant variability in both warfarin pharmacokinetics and pharmacodynamics makes achieving therapeutic drug levels a challenge. Researchers are now investigating whether adding genomic information to dosing algorithms could better identify the optimal starting dose for patients new to warfarin, minimize variability in drug response, […]

  • Choosing Between Treatment Strategies for Patients With Acquired Hemophilia A Monday, October 3rd, 2016 | October 2016, Volume 2, Issue 10 | Alice Ma, MD

    Acquired hemophilia A (AHA) is a rare bleeding disorder in which patients develop inhibitors against clotting factors – most often factor VIII (FVIII). For nearly 10 years, the standard of care for the treatment of AHA was either recombinant factor VIIa (rFVIIa) or FVIII inhibitor bypass activity (FEIBA), known as a “bypassing agent” because it […]

  • FLT3 Inhibitors in Older Patients with Acute Myeloid Leukemia: More Questions Than Answers? Friday, June 24th, 2016 | July 2016, Volume 2, Issue 7 | Richard M. Stone, MD

    Acute myeloid leukemia (AML) affects primarily older adults (with a median age of 67 years at diagnosis), and management of the disease in this population represents a therapeutic challenge – given their comorbidities and susceptibility to treatment-related toxicities. Patients who also harbor the FLT3 mutation face a particularly poor prognosis, with a high chance of […]

  • Optimal Timing of Transplant in Myeloma Tuesday, February 2nd, 2016 | February 2016, Volume 2, Issue 2 | Shaji Kumar, MD

    New therapeutic options for the treatment of multiple myeloma are capable of achieving sustained and deep remissions, calling into question the role of upfront stem cell transplantation. ASH Clinical News has invited Shaji Kumar, MD, and Ola Landgren, MD, to debate the question: “What is the optimal timing for hematopoietic cell transplantation in patients with […]

  • Should IVC Filters Still Be Inserted into Thrombosis Management Guidelines? Thursday, November 19th, 2015 | December 2015, Volume 1, Issue 12 | Joseph M. Stavas, MD

    Although the use of inferior vena cava (IVC) filters to prevent thrombosis has increased dramatically in the past decade, the risk-benefit ratio of these devices is unclear. The potential complications associated with filter placement and retrieval may outweigh the benefit, particularly in the era of novel oral anticoagulants. ASH Clinical News invited Joseph M. Stavas, […]

1 of 3
back to top